MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma
Yin-Ping Fan(Tongji Hospital), Xingxing He(Wuhan University), Guangya Xiang(Centre for Higher Education), Jiazhi Liao(Tongji University), Feng Ye(Sichuan University), Yaqi Lu, Pengxuan Zhao(Hainan Medical University), Wang-xian Tang(Tongji Hospital), Dean Tian(Tongji Hospital)
Cited by 81
Related Papers
Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis
|Journal of Hepatology|2021|378
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets
|Journal of Experimental & Clinical Cancer Research|2021|216
CXCL9: evidence and contradictions for its role in tumor progression
|Cancer Medicine|2016|177
The role of autophagy in hepatocellular carcinoma: friend or foe
|Oncotarget|2017|152
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition
|Experimental Hematology and Oncology|2021|101